Ilika targets neuromodulation market with medical battery offering

Ilika Plc

Ilika has confirmed it will be exhibiting at NANS 2026, the North American Neuromodulation Society’s flagship annual meeting, alongside Cirtec Medical.

NANS 2026 is the most prominent neuromodulation event in North America, bringing together medical-device companies, clinicians, and researchers focused on spinal cord stimulation, pain management, and implantable neurotechnologies. With nearly 500 scientific abstracts already accepted, including 312 focused on new research, the event points to growing clinical demand and increasing innovation across the sector.

Solid-state batteries are particularly well suited for implanted medical devices. They are safer than lithium-ion, with no liquid electrolyte and a lower risk of leakage or thermal runaway. They also offer better reliability and longer life in small formats, which is critical for applications like neurostimulators and miniaturised therapeutic devices.

While its Goliath programme remains focused on large-format batteries for electric vehicles and industrial electrification, Stereax targets a different end market entirely. The medical device sector is growing, largely independent of broader macroeconomic cycles, and increasingly reliant on battery innovations to support smaller, safer and more intelligent implants.

Ilika plc (LON:IKA) is a pioneer in solid state battery technology enabling solutions for applications in Industrial IoT, MedTech, Electric Vehicles and Consumer Electronics.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika builds the manufacturing path for Goliath solid-state batteries

Ilika is building the manufacturing and licensing pathway needed to move its Goliath solid-state battery technology towards larger-scale commercial production.

Ilika: Stereax revenue growth and Goliath opportunities ahead

Morphose Capital Partners’ Dr Tom McColm discusses Ilika’s FY26 results, the outlook for Stereax commercial revenues, progress with Goliath and potential opportunities in automotive, defence and e-bikes.

Ilika CEO highlights Stereax revenue growth and Goliath defence interest

Ilika CEO Graeme Purdy discusses Stereax product revenue, planned M300 battery deliveries, Goliath 10Ah development, EV market trends and rising demand from the defence sector.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Ilika plc: Stereax Revenue Arrives as Goliath Draws Defence Interest (video)

Ilika plc CEO Graeme Purdy outlines how Stereax has started generating product-related revenue, why M300 battery deliveries remain on track and how Goliath’s 10Ah prototype is opening new opportunities in defence and sovereign battery supply.

Ilika builds commercial momentum across Stereax and Goliath batteries

Ilika Plc reports annual results for the year ended 30 April 2026, highlighting progress on its Stereax medical battery line and Goliath large-format batteries for EV, defence and consumer applications. The company began Stereax production and deliveries, shipped larger Goliath prototypes, secured further grant funding and raised £5 million post-period to accelerate commercialisation.

Search